Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.64 |
| ▸ | PLIN1 | O60240 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | RECQL | P46063 | 2/20 | 0.64 |
| ▸ | PLIN5 | Q00G26 | 2/20 | 0.64 |
| ▸ | ABHD5 | Q8WTS1 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | F3 | P13726 | 2/20 | 0.64 |
| ▸ | TNKS | O95271 | 1/20 | 0.64 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.64 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4023735 | 1.00 | MAPT (0.64) | MAPTHDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL9113056 | 0.88 | TDP1 (0.62) | MAPTHDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL9113048 | 0.88 | TDP1 (0.62) | MAPTHDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL16588259 | 0.84 | HDAC1 (0.61) | MAPTHDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL11476908 | 0.83 | TDP1 (0.61) | MAPTHDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL29111191 | 0.83 | MAPT (0.59) | MAPTHDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL11476916 | 0.83 | TDP1 (0.61) | MAPTHDAC3HDAC4HDAC1HDAC2 | |
| Cinnamic Acid SCHEMBL2816657 | 0.81 | HCAR2 (0.95) | MAPTHDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL27560284 | 0.81 | MAPT (0.57) | MAPTHDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL1949536 | 0.79 | MAPT (0.55) | MAPTHDAC3HDAC4HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299388-B1 | VARIOLIN DERIVATIVES AS ANTI-CANCER AGENTS | PHARMA MAR SA (ES) | 2009-05-13 | — | — | EP | claimed |
| US-7320981-B2 | Antitumor agents | PHARMA MAR, S.A. (ES) | 2008-01-22 | — | — | US | claimed |
| US-20050014778-A1 | Variolin derivatives as anti-cancer agents | PHARMA MAR, S.A. (ES) | 2005-01-20 | — | — | US | claimed |
| EP-1299388-A1 | VARIOLIN DERIVATIVES AS ANTI-CANCER AGENTS | PHARMA MAR, S.A. (ES) | 2003-04-09 | — | — | EP | claimed |
| WO-2002004447-A1 | VARIOLIN DERIVATIVES AS ANTI-CANCER AGENTS | PHARMA MAR, S.A. (ES) | 2002-01-17 | — | — | WO | claimed |
| EP-1299388-B1 | VARIOLIN DERIVATIVES AS ANTI-CANCER AGENTS | PHARMA MAR SA (ES) | 2009-05-13 | — | — | EP | disclosed |
| US-7320981-B2 | Antitumor agents | PHARMA MAR, S.A. (ES) | 2008-01-22 | — | — | US | disclosed |
| US-7094516-B2 | Benzobisazole compound and optical recording medium containing the compound | MITSUI CHEMICALS, INC. (JP) | 2006-08-22 | — | — | US | disclosed |
| EP-1247655-B1 | OPTICAL RECORDING MEDIUM AND NOVEL AZAPORPHYRIN COMPOUNDS | MITSUI CHEMICALS INC (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | MITSUI CHEMICALS, INC. (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1262966-B1 | Optical recording medium and novel azaporphyrin compound | MITSUI CHEMICALS INC (JP) | 2006-04-12 | — | — | EP | disclosed |
| US-6969764-B2 | Mono-, di-, and triazaporphyrin compounds optionally in the form of a metal or metalloid complex | MITSUI CHEMICALS, INC. (JP) | 2005-11-29 | — | — | US | disclosed |
| US-6627288-B1 | Optical recording medium and porphycene compound | MITSUI CHEMICALS, INC. (JP) | 2003-09-30 | — | — | US | disclosed |
| US-20030091931-A1 | Benzbisazole compound and optical recording medium containing the compound | MITSUI CHEMICALS, INC. (JP) | 2003-05-15 | — | — | US | disclosed |
| EP-1299388-A1 | VARIOLIN DERIVATIVES AS ANTI-CANCER AGENTS | PHARMA MAR, S.A. (ES) | 2003-04-09 | — | — | EP | disclosed |
| EP-1262966-A2 | Optical recording medium and novel azaporphyrin compound | Mitsui Chemicals, Inc. (JP) | 2002-12-04 | — | — | EP | disclosed |
| EP-1247655-A1 | OPTICAL RECORDING MEDIUM AND NOVEL AZAPORPHYRIN COMPOUNDS | Mitsui Chemicals, Inc. (JP) | 2002-10-09 | — | — | EP | disclosed |
| EP-1245571-A1 | BENZBISAZOLE COMPOUND AND OPTICAL RECORDING MEDIUM CONTAINING THE COMPOUND | Mitsui Chemicals, Inc. (JP) | 2002-10-02 | — | — | EP | disclosed |
| EP-1180765-A1 | Optical recording medium and porphycene compound | Mitsui Chemicals, Inc. (JP) | 2002-02-20 | — | — | EP | disclosed |
| WO-2002004447-A1 | VARIOLIN DERIVATIVES AS ANTI-CANCER AGENTS | PHARMA MAR, S.A. (ES) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030091931-A1 | Benzbisazole compound and optical recording medium containing the compound | DAO, CACNA1I, KCNB2 | MAPT 3650/4885HDAC3 2148/4885HDAC4 2865/4885 |
| US-20050014778-A1 | Variolin derivatives as anti-cancer agents | CBR3, CCNL2, CBR1 | MAPT 4689/4885HDAC3 175/4885HDAC4 715/4885 |
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | ALPG, TRPC6, GNRHR | MAPT 843/4885HDAC3 4298/4885HDAC4 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.